Herding an atypical syndicate

Unlike its gene editing peers that are going deep into therapeutics, Caribou Biosciences Inc. has been going wide, exploring numerous sectors where its CRISPR-Cas9 technology could be applied. With last week's $30 million series B round, Caribou has recruited a venture syndicate with expertise in the sectors where it wants to focus.

Caribou raised $11 million in a series A round in April 2015 and used the money to build out its platform, including wet labs and computational technologies...